Back to search results

Study of LY3457263 for Type 2 Diabetes

This study is looking for people with Type 2 Diabetes whose blood sugar (HbA1c) is not well-controlled, even though they are already taking stable doses of semaglutide or tirzepatide. The study will compare a new medicine, LY3457263, to a placebo (an inactive substance) to see if LY3457263 can help lower HbA1c levels. To join, you need to be between 18 and 75 years old, have an HbA1c between 7.5% and 10.5%, and a body mass index (BMI) of 27 or higher. The study aims to enroll 240 participants and will last about 9 months. The main goal is to measure the change in HbA1c after 24 weeks.

Study design
This is an interventional study comparing LY3457263 to a placebo, with a planned enrollment of 240 participants.
What's involved
Participation in the study will last about 9 months. The primary endpoint, change in HbA1c, is measured at Baseline and Week 24.
Compensation
Not stated in the trial record.
Follow-up
Not specified.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06897475

A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide

Recruiting
PHASE2Ages 18–75InterventionalTreatment
Eli Lilly and Company
~240 participants
Updated 2026-08-21 on ClinicalTrials.gov
What's tested:LY3457263Placebo

At a glance

Recruiting sites
56 of 60 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Change from Baseline in Hemoglobin A1c (HbA1c)
Measured over Baseline, Week 24

Conditions

Type 2 Diabetes

Explore related trials

ObesityOverweightType 2 Diabetes Mellitus

Where it's being run

60 sites across 19 states
United Kingdom10
Canada9
Poland9
Texas5
Germany5
Georgia4
New York3
Florida2

Study leadership

  • Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST) · STUDY_DIRECTOR · Eli Lilly and Company

Who to contact

Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
[email protected]
1-317-615-4559
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Have type 2 diabetes
Have HbA1c ≥7.5% to ≤10.5% at screening
Have a body mass index (BMI) of ≥27 kilograms per square meter (kg/m2) at screening
Have had a stable body weight for the three months prior to screening
On stable treatment dose of one of the following incretins for at least three months prior to screening:
Injectable semaglutide (1 and 2 milligram (mg))
Injectable tirzepatide (5, 7.5, 10, 12.5 and 15 mg)

Exclusion

Have type 1 diabetes, latent autoimmune diabetes, or history of ketoacidosis or hyperosmolar coma
Have a prior or planned surgical treatment for obesity
Have any of the following cardiovascular conditions within three months prior to screening:
acute myocardial infarction
cerebrovascular accident (stroke)
unstable angina, or
hospitalization due to congestive heart failure
Have used insulin to control blood glucose within the past year (short-term use allowed)
Current use of prohibited oral antihyperglycemic medication (OAM) (including but not limited to, Dipeptidyl Peptidase IV Inhibitors (DPP-4i) and meglitinides) may be randomized if the prohibited OAM treatment was discontinued at least 3 months prior to screening
If participant has been on stable doses (for at least three months) of up to three permitted OAMs (limited to metformin, sodium-glucose cotransporter-2 (SGLT2) inhibitors, alpha-glucosidase inhibitors, sulfonylurea, and/or thiazolidinediones (TZD), they are permitted to participate in the study
Have taken any medications or alternative remedies for weight loss within three months prior to screening

What this trial measures

  • Change from Baseline in Hemoglobin A1c (HbA1c)Baseline, Week 24